|
4 Companies |
|
4 Products |
|
4 Products |
|
7 Mechanisms of Action |
|
0 Trials |
|
10 News |
|
- | NN1213 / Novo Nordisk
Trial completion: OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease (clinicaltrials.gov) - Jun 30, 2017
P2, N=30, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
No longer recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Biomarker, Trial completion, IO biomarker: OMS: Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome (clinicaltrials.gov) - May 23, 2017
P=N/A, N=400, Completed, Sponsor: National Pediatric Neuroinflammation Organization, Inc.
No longer recruiting --> Completed Recruiting --> Completed
- zonisamide / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: EpsilonZ (clinicaltrials.gov) - Apr 25, 2015
P3, N=24, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Recruiting --> Completed | N=32 --> 24 | Trial primary completion date: Feb 2015 --> Jul 2014
- zonisamide / Generic mfg.
New P3 trial: EpsilonZ (clinicaltrials.gov) - Mar 5, 2013
P3, N=32, Recruiting, Sponsor: Assistance Publique - H
- Trial termination: Pilot Efficacy Study of T2000 in Myoclonus Dystonia (clinicaltrials.gov) - Oct 24, 2011
P2, N=5, Terminated, Sponsor: Taro Pharmaceuticals USA
Recruiting --> Completed | N=32 --> 24 | Trial primary completion date: Feb 2015 --> Jul 2014 Recruiting --> Terminated; Slow Recruitment of eligible patients